Holen Sie sich die Stockscreener-App
13.68
2.09%
0.28
Handel nachbörslich:
13.78
0.10
+0.73%
Schlusskurs vom Vortag:
$13.40
Offen:
$13.64
24-Stunden-Volumen:
290.30K
Relative Volume:
0.39
Marktkapitalisierung:
$1.75B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-6.3468
EPS:
-2.1554
Netto-Cashflow:
-
1W Leistung:
+0.74%
1M Leistung:
-16.94%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.50
$14.25
1-Wochen-Bereich:
$13.22
$14.58
52-Wochen-Spanne:
$11.00
$18.18
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
888-469-0055
Adresse
101 SOUTH STREET, SUITE 900, SOMERVILLE
Compare GENB vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
13.68 | 1.72B | 0 | 0 | 0 | -2.1554 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Eingeleitet | Goldman | Buy |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2026-03-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-24 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
JPMorgan Small Cap Value Portfolio's Generate Biomedicines Inc(GENB) Holding History - GuruFocus
Generate Biomedicines, Inc. (GENB) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
If You Invested $1,000 in Generate Biomedicines (GENB) - Stock Titan
Price to cash flow ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Surges 5.96% – Support and Resistance Levels in FocusVolatility Stop - dars.gov.et
Price to sales forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Generate Biomedicines (GENB) Consolidates Near Upper Bound as Bulls Test ResistanceRegression Channel - dars.gov.et
Price to earnings forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Number of shareholders of Generate Biomedicines, Inc. – BX:GENB - TradingView
What Just Happened with Generate Biomedicines' IPO - Kavout | AI
Generate Biomedicines (GENB) Earnings Date and Reports 2026 - MarketBeat
Generate Biomedicines (GENB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Nvidia Invests in Biotech Company Generate Biomedicines - Intellectia AI
Significant Drop for Generate Biomedicines (GENB) as Shares Decl - GuruFocus
Generate Biomedicines Plunges As Rally Suddenly Unwinds - TipRanks
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference - AOL.com
Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday - The Motley Fool
EBITDA of Generate Biomedicines, Inc. – BX:GENB - TradingView
GENBGenerate Biomedicines Inc Dividends - Finviz
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price to book forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Price to book forward of Generate Biomedicines, Inc. – BX:GENB - TradingView
Q&A: Generate Biomedicines CTO talks AI advancements - TechTarget
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Index - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Value Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2000 Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 3000E Growth Benchmark - marketscreener.com
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to Russell 2500 Value Benchmark - marketscreener.com
Generate Biomedicines (GENB) Holds Near Support as Biotech Sector Shows Mixed SignalsPut Spread Alert - Bölüm Sonu Canavarı
Generate Biomedicines stock ends week back above IPO price as volume jumps - TechStock²
Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market - The Motley Fool
Transcript : Generate Biomedicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 03 - marketscreener.com
Enterprise value to EBITDA forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Drone startup Elroy Air to list on Nasdaq via $1 billion SPAC deal - Reuters
Enterprise value to EBIT forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (NASDAQ:GENB) - TradingView
Generate Biomedicines, Inc. Actuals & Estimates (BOATS:GENB) - TradingView
Price to sales forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
Price to earnings forward of Generate Biomedicines, Inc. – BOATS:GENB - TradingView
GENB Forecast — Price Target — Prediction for 2027 - TradingView
Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Morgan Stanley Boosts Generate Biomedicines Price Target to 22 Dollars - sekbernews.id
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) - Yahoo Finance
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts - Sahm
Generate Biomedicines (GENB) Surges 9.7%: Key Levels and What Lies AheadPrice Action Signals - dars.gov.et
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to S&P TMI Index - marketscreener.com
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):